The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid ...

Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing the investigational therapy Haduviotm (oral nalbuphine ER) for the treatment of chronic cough in patients with ...

Seaport Therapeutics management team will present at Stifel 2025 Healthcare Conference on November 11 at 10:00AM EST.

Stifel raised the firm’s price target on Exact Sciences (EXAS) to $80 from $67 and keeps a Buy rating on the shares. With a Q3 top-line beat and ...

2. Mergers and acquisitions are picking up: So far this year, buyouts have boosted several biotech stocks. Some standouts: Regulus Therapeutics went up 120%; 89bio went up 85%; Chimerix gained 69% and ...

Stifel downgraded Ichor Holdings (ICHR) to Hold from Buy with a price target of $21, down from $23. The company missed Q3 estimates and its Q4 ...

A. O. Smith Corporation (NYSE: AOS) is included among the 13 Best Consistent Dividend Stocks to Buy Now.

With the 2025-26 season on the horizon, Copper Mountain is gearing up for a season full of fresh turns, events and ...

The Base Shelf Prospectus is accessible, and the Prospectus Supplement will be accessible within two business days, through SEDAR+ /NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR ...

Solventum (NYSE: SOLV) announced today its executives will participate in a fireside chat at the Stifel Healthcare Conference ...

Philip Morris International Inc. (NYSE:PM) is one of billionaire Daniel Sundheim’s stock picks with huge upside potential.

Stifel CEO Ron Kruszewski wants to be clear: His company isn’t for sale. Kruszewski told employees just that in a memo on ...